BIAF News
bioAffinity Technologies Highlights Importance of Link Between Early Lung Cancer Detection and Curative Treatment During National Lung Cancer Awareness Month
In recognition of National Lung Cancer Awareness Month, bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company addressing the need for early lung cancer detection with its noninvasive CyPath Lung test, will join physicians, patients and other healthcare providers at the Lung...
Business Wire
bioAffinity Technologies Highlights Importance of Link Between Early Lung Cancer Detection and Curative Treatment During National Lung Cancer Awareness Month
In recognition of National Lung Cancer Awareness Month, bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company addressing the need for early lung cancer detection with its noninvasive CyPath Lung test, will join physicians, patients and other healthcare providers at the Lung...
Business Wire
bioAffinity Technologies to Present New Perspectives on CyPath Lungs Use for Cancer Risk Assessment at CHEST 2026
bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company developing noninvasive healthcare solutions for the early detection and monitoring of lung disease, will sponsor a Learning Theater presentation at CHEST 2026, the annual meeting of the American College of Chest...
Business Wire
bioAffinity Technologies to Present Positive Research Data in Development of Its New Test Measuring Asthma and COPD-Related Lung Inflammation and Drug-Related Receptors at CHEST 2026
bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company developing noninvasive healthcare solutions for the early detection and monitoring of lung disease, today announced it will present new data at CHEST 2026, the annual meeting of the American College of Chest Physicians...
Business Wire
WallachBeth Capital Announces Closing of bioAffinity Technologies $4 Million Registered Direct Financing of Common Stock and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules
WallachBeth Capital Announces Closing of bioAffinity Technologies $4 Million Registered Direct Financing of Common Stock and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules WallachBeth Capital Announces Closing of bioAffinity Technologies $4 Million Registered Direct Financing...
PR Newswire
bioAffinity Technologies, Inc. Announces Closing of $4 Million Registered Direct Financing of Common Stock and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules
bioAffinity Technologies, Inc. (NASDAQ: BIAF, BIAFW), a biotechnology company developing noninvasive healthcare solutions for the early detection and monitoring of lung disease, today announced that it has closed its previously announced registered direct offering of shares of common stock (or...
Business Wire
WallachBeth Capital Announces bioAffinity Technologies Approximately $4 Million Registered Direct Financing of Common Stock and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules
WallachBeth Capital Announces bioAffinity Technologies Approximately $4 Million Registered Direct Financing of Common Stock and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules WallachBeth Capital Announces bioAffinity Technologies Approximately $4 Million Registered Direct...
PR Newswire
bioAffinity Technologies, Inc. Announces Approximately $4 Million Registered Direct Financing of Common Stock and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules
bioAffinity Technologies, Inc. (NASDAQ: BIAF, BIAFW) a biotechnology company developing noninvasive healthcare solutions for the early detection and monitoring of lung disease, today announced that it has entered into a definitive agreement with an institutional investor to sell shares of common...
Business Wire
These Stocks are Lighting it Up
These names stand out for very different reasons: NeOnc Technologies (NASDAQ:NTHI), Hyperfine (NASDAQ:HYPR), bioAffinity Technologies (NASDAQ:BIAF), Profound Medical (NASDAQ:PROF), Wolfspeed (NYSE: WOLF) and Sunshine Biopharma (NASDAQ:SBFM).
24-7 Market News
bioAffinity’s Lung-Cancer AI Gets Japanese Patent Boost as CyPath Lung Sales Surge
bioAffinity Technologies (NASDAQ:BIAF) is adding another layer of protection around its most important commercial asset just as adoption of its CyPath Lung diagnostic is accelerating.
24-7 Market News
bioAffinity Technologies Announces Notification of Japanese Patent Allowance Covering Noninvasive CyPath Lung and AI-Built Algorithm
bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive tests for the detection of early-stage lung cancer and other lung diseases, today announced that the Japan Patent Office has issued a Notice of Allowance indicating its intention to...
Business Wire